279 results on '"Martino, Enrica A."'
Search Results
52. The Effects of Fiscal Decentralisation on Publicly Provided Services and Labour Markets
53. Myelodysplastic syndromes with ring sideroblasts
54. Iron chelation therapy
55. Wealth inequalities among seniors: the role of marital histories across cohorts
56. The “kissing sign” of liver and spleen
57. Safety and efficacy of caplacizumab in a case of thrombotic thrombocytopenic purpura in the postpartum period
58. Elotuzumab in multiple myeloma
59. Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials
60. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials
61. The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents
62. Correction to: Non cognitive skills and childcare attendance
63. Non cognitive skills and childcare attendance
64. Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma
65. Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials.
66. Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients
67. Eltrombopag treatment for severe immune thrombocytopenia during pregnancy: a case report
68. Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia
69. Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities
70. Salvage Autologous Stem Cell Transplant for the Treatment of First Relapse Multiple Myeloma: Evidence of Its Clinical Role from a Multicenter Italian Study
71. Lenalidomide Maintenance after VTD Induction and Autologous Stem Cell Transplantation: An Italian Real-Life Study of 558 Patients
72. Ibrutinib As First Line Therapy in Chronic Lymphocytic Leukemia Patients over 80 Years Old: A Retrospective Real-Life Multicenter Italian Cohort
73. CD49d Expression Is Included in a Revised 4-Factor Model Predicting Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Multi-Center Real-World Experience
74. TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases
75. A Case of Immune Thrombocytopenia After COVID-19 Vaccination: Coincidental or Causal Effect? Running Title: ITP After COVID-19 Vaccination
76. Effectiveness of ibrutinib as first‐line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab‐bendamustine: Results of study on 486 cases outside clinical trials
77. Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
78. Validation of the Alternative International Prognostic Score‐E (AIPS‐E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O‐CLL1‐GISL protocol
79. Biblioteche, strumenti e materiali per la didattica universitaria: dalla pergamena al digitale
80. The Effects Of Fiscal Decentralization On Publicly Provided Services And Labor Markets.
81. Elotuzumab in multiple myeloma
82. Diplopia and hemianopsia as initial manifestations of multicentric Castleman disease successfully treated with siltuximab.
83. Assessment of the 4‐factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study
84. Chemotherapy-based regimens in multiple myeloma in 2020
85. Comparison of ibrutinib and idelalisib plus rituximab in real‐life relapsed/resistant chronic lymphocytic leukemia cases
86. Differential Treatment Strategy in Polycythemia Vera Patients with Stable Suboptimal Response to Hydroxyurea: Clinical Correlations and Impact on Survival
87. First Line Treatment with Hydroxyurea in Patients with Policitemia Vera: Evaluation of Efficacy in the Current Clinical Practice Beyond ELN Criteria
88. Role of Age, Fitness and Concomitant Medications in CLL Patients Treated with Venetoclax
89. Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
90. Evidence-based application of explicit criteria to assess the appropriateness of geriatric prescriptions at admission and hospital stay
91. Avoiding taxes by transfers within the family
92. Safety and efficacy of caplacizumab in a case of thrombotic thrombocytopenic purpura in the postpartum period.
93. Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients.
94. Primary diffuse cutaneous plasmacytoma: when a correct clinico-pathologic approach is mandatory for the patient's health
95. Additional file 1: of Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial
96. Early Education and Gender Differences
97. Biblioteche, strumenti e materiali per la didattica universitaria: dalla pergamena al digitale
98. Disuguaglianze di genere nel mercato del lavoro: l'impatto del Bonus Infanzia e del congedo di paternità
99. Early Salvage Treatment with Second-Generation Novel Agents at Biochemical Relapse Prolongs Overall Survival: A Real-World Single Center Experience
100. Mannosylation of the Tumor Immunoglobulin Variable Region Informs Cell of Origin and Environmental Interactions in DLBCL Subsets
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.